| Story Views | |
| Now: | |
| Last Hour: | |
| Last 24 Hours: | |
| Total: | |
New FDA Dictator
The new FDA Commissioner, Robert Califf, has the credentials one would expect is needed to head the FDA in the 21st century. A disclosure on the website of the Duke Clinical Research Institute reads:
Robert M. Califf, MD, reports receiving research grant support from Novartis Pharmaceuticals, Johnson & Johnson/Scios, Lilly, Merck, and Schering Plough, and consulting fees from Annenberg, Aterovax, Bayer/Ortho McNeil, BMS, Boehringer Ingelheim, GSK, WebMd/theheart.org, Johnson andJohnson/Scios, Kowa Research Institute, McKinsey & Company, Medtronic, Merck, Novartis Pharmaceuticals, Sanofi Aventis, and Schering Plough, and has an equity position with NITROX, LLC.
Pharma Marketing News also reports:
In disclosure information for a 2013 article in Circulation, Dr. Califf’s also lists financial links to Gambro, Regeneron, Gilead, AstraZeneca, Roche, others companies and equity positions in four medical companies. The medical website Medscape discloses that Dr. Califf “served as a director, officer, partner, employee, advisor, consultant or trustee for Genentech” as well as for Medscape LLC/theheart.org. Portola Pharmaceuticals says Dr. Califf served on the Board of Directors until he was appointed FDA Deputy Commissioner for Medical Products and Tobacco.”
Shocking, I know. And this is all in the interest of protecting and promoting the public health.
Source: http://karendecoster.com/new-fda-dictator.html
